Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

被引：0
|
作者：
Diamond, Benjamin
Jayabalan, David S.
Pearse, Roger
Perry, Art
Pekle, Karen
Niesvizky, Ruben
Rossi, Adriana C.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3102
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The role of carfilzomib in treatment of newly diagnosed multiple myeloma
    Strifler, Susanne
    Knop, Stefan
    FUTURE ONCOLOGY, 2018, 14 (30) : 3123 - 3134
  • [2] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [3] Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients
    Palumbo, Antonio
    Bringhen, Sara
    Villani, Oreste
    Siniscalchi, Agostina
    Russo, Eleonora
    Uccello, Giuseppina
    Cerrato, Chiara
    Gilestro, Milena
    Rossi, Davide
    Boccadoro, Mario
    BLOOD, 2012, 120 (21)
  • [4] Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
    Ola Landgren
    Pieter Sonneveld
    Andrzej Jakubowiak
    Mohamad Mohty
    Karim S. Iskander
    Khalid Mezzi
    David S. Siegel
    Leukemia, 2019, 33 : 2127 - 2143
  • [5] Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
    Landgren, Ola
    Sonneveld, Pieter
    Jakubowiak, Andrzej
    Mohty, Mohamad
    Iskander, Karim S.
    Mezzi, Khalid
    Siegel, David S.
    LEUKEMIA, 2019, 33 (09) : 2127 - 2143
  • [6] Daratumumab proves effective in patients with newly diagnosed multiple myeloma
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2018, 15 : 136 - 136
  • [7] Daratumumab proves effective in patients with newly diagnosed multiple myeloma
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (03) : 136 - 136
  • [8] Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
    Jasielec, Jagoda K.
    Kubicki, Tadeusz
    Raje, Noopur
    Vij, Ravi
    Reece, Donna
    Berdeja, Jesus
    Derman, Benjamin A.
    Rosenbaum, Cara A.
    Richardson, Paul
    Gurbuxani, Sandeep
    Major, Sarah
    Wolfe, Brittany
    Stefka, Andrew T.
    Stephens, Leonor
    Tinari, Kathryn M.
    Hycner, Tyler
    Rojek, Alexandra E.
    Dytfeld, Dominik
    Griffith, Kent A.
    Zimmerman, Todd M.
    Jakubowiak, Andrzej J.
    BLOOD, 2020, 136 (22) : 2513 - 2523
  • [9] Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
    Saburi, Masuho
    Ogata, Masao
    Soga, Yasuhiro
    Kondo, Yoshiyuki
    Kurimoto, Ryo
    Itani, Kazuhito
    Kohno, Kazuhiro
    Uchida, Hiroki
    Nakayama, Toshiyuki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2020, 60 (01) : 17 - 20
  • [10] Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
    Bringhen, Sara
    Petrucci, Maria Teresa
    Larocca, Alessandra
    Conticello, Concetta
    Rossi, Davide
    Magarotto, Valeria
    Musto, Pellegrino
    Boccadifuoco, Luana
    Offidani, Massimo
    Omede, Paola
    Gentilini, Fabiana
    Ciccone, Giovannino
    Benevolo, Giulia
    Genuardi, Mariella
    Montefusco, Vittorio
    Oliva, Stefania
    Caravita, Tommaso
    Tacchetti, Paola
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    BLOOD, 2014, 124 (01) : 63 - 69
12345